Breaking News

How a restless leg syndrome drug wrecked one man's life

February 4, 2026
Psilocybin is derived from so-called magic mushrooms.
John Moore/Getty Images

STAT+ | Trump administration officials blocked FDA effort to fast-track review of psychedelic treatment

Trump officials halted FDA plans to fast-track a psilocybin depression drug, revealing possible discord between officials and MAHA's psychedelic allies.

By Lizzy Lawrence, Elaine Chen, and Damian Garde


STAT+ | FTC settles lawsuit with Express Scripts over charges it manipulated insulin prices, impeded access

Express Scripts, which is owned by Cigna, must make several 'fundamental changes' to its dealings with employers, health plans, and pharmacies.

By Ed Silverman


STAT+ | Epic launches AI Charting, potentially scrambling the ambient scribe market

Epic Systems announced more details around its long-anticipated AI Charting feature, which could disrupt the market for ambient scribes.

By Brittany Trang



Justin Sullivan/Getty Images

Opinion: I spent nearly 20 years on a drug for restless leg syndrome. It wrecked my life

Pramipexole for restless leg syndrome and Parkinson's can cause compulsive behaviors. Doctors don't always warn patients.

By J. Aaron Sanders


Opinion: Measles in an ICE facility is a public health failure

A measles outbreak in a Texas immigration detention center was foreseeable, preventable, and rooted in policy choices that neglect basic public health.

By Krutika Kuppalli


STAT+ | FDA Commissioner Marty Makary tries to soothe staff concerns over voucher program

At an employee town hall, Food and Drug Administration leaders tried to quell staff concerns about the Commissioner's National Priority Voucher.

By Lizzy Lawrence


Christopher Liu.
Courtesy Jack Liu

Junior scientists face a quandary when starting their own labs: How far to stray from the hive

Research suggests early-career scientists benefit from some overlap with advisers' work, but too much can backfire once independence begins.

By Jonathan Wosen


New PBM law could open door to direct sales between employers, drugmakers

The pharmacy benefit manager reforms prohibits PBMs from linking their payments to drug prices in Medicare and require more transparency

By John Wilkerson


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Daily Recap? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2026, All Rights Reserved.

No comments